title: Novel insight into the pathobiology of abdominal aortic aneurysm and potential future treatment concepts.
abstract: The patient with abdominal aortic aneurysm (AAA) commonly is a nondiabetic, white man with a history of smoking. Moreover, AAA represents a leading cause of death in elderly men in Western countries. The purpose of this manuscript is to review current evidence as to the pathobiology of AAA as well as potential future drug targets to prevent progression of AAA.
authors.affiliation: Division of Clinical and Interventional Angiology, Swiss Cardiovascular Center, University Hospital and University of Bern, Bern, Switzerland.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Diehm
authors.forename: Florian
authors.initials: F
authors.lastname: Dick
authors.forename: Thomas
authors.initials: T
authors.lastname: Schaffner
authors.forename: Juerg
authors.initials: J
authors.lastname: Schmidli
authors.forename: Christoph
authors.initials: C
authors.lastname: Kalka
authors.forename: Stefano
authors.initials: S
authors.lastname: Di Santo
authors.forename: Jan
authors.initials: J
authors.lastname: Voelzmann
authors.forename: Iris
authors.initials: I
authors.lastname: Baumgartner
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001011:Aorta / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism / Q000473:pathology*; D017544:Aortic Aneurysm, Abdominal / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D050197:Atherosclerosis / Q000150:complications / Q000473:pathology; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007249:Inflammation / Q000150:complications / Q000473:pathology; D048670:MAP Kinase Kinase 4 / Q000037:antagonists & inhibitors / Q000378:metabolism; D008297:Male; D018384:Oxidative Stress; D010447:Peptide Hydrolases / Q000378:metabolism; D011480:Protease Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D014815:Vitamins / Q000627:therapeutic use
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D016326:Extracellular Matrix Proteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011480:Protease Inhibitors; D014815:Vitamins; D048670:MAP Kinase Kinase 4; D010447:Peptide Hydrolases